Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension | 30 | 2023 | 978 | 4.310 |
Why?
|
Antihypertensive Agents | 22 | 2023 | 378 | 3.020 |
Why?
|
Blood Pressure | 27 | 2023 | 861 | 2.720 |
Why?
|
Blood Pressure Determination | 9 | 2020 | 92 | 2.060 |
Why?
|
Dementia | 10 | 2023 | 231 | 1.710 |
Why?
|
Humans | 100 | 2023 | 28304 | 1.260 |
Why?
|
Cardiovascular Diseases | 14 | 2023 | 1059 | 1.230 |
Why?
|
Female | 72 | 2023 | 17679 | 1.120 |
Why?
|
Male | 67 | 2023 | 16967 | 1.070 |
Why?
|
Anemia, Sickle Cell | 6 | 2010 | 40 | 1.050 |
Why?
|
Aged | 45 | 2023 | 9256 | 1.030 |
Why?
|
Health Status | 6 | 2017 | 360 | 1.030 |
Why?
|
Anthrax Vaccines | 3 | 2013 | 4 | 0.960 |
Why?
|
Antibody Formation | 4 | 2013 | 38 | 0.950 |
Why?
|
Renal Insufficiency, Chronic | 7 | 2021 | 272 | 0.940 |
Why?
|
Nursing Homes | 1 | 2023 | 32 | 0.910 |
Why?
|
Medicare | 3 | 2023 | 181 | 0.880 |
Why?
|
Obesity | 13 | 2023 | 1079 | 0.870 |
Why?
|
Middle Aged | 41 | 2023 | 10678 | 0.840 |
Why?
|
Genome-Wide Association Study | 11 | 2015 | 615 | 0.840 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 441 | 0.830 |
Why?
|
Severity of Illness Index | 5 | 2020 | 846 | 0.800 |
Why?
|
Myocardial Infarction | 5 | 2023 | 418 | 0.790 |
Why?
|
Diabetes Mellitus, Type 2 | 10 | 2023 | 1556 | 0.790 |
Why?
|
Electronic Health Records | 3 | 2023 | 117 | 0.770 |
Why?
|
Life Style | 7 | 2023 | 372 | 0.750 |
Why?
|
Ethnic Groups | 7 | 2017 | 450 | 0.710 |
Why?
|
Polymorphism, Single Nucleotide | 16 | 2017 | 1236 | 0.700 |
Why?
|
Mobility Limitation | 2 | 2017 | 180 | 0.700 |
Why?
|
Aged, 80 and over | 16 | 2023 | 3562 | 0.670 |
Why?
|
Wet Macular Degeneration | 1 | 2017 | 2 | 0.640 |
Why?
|
Quality of Life | 5 | 2010 | 792 | 0.630 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 154 | 0.620 |
Why?
|
Visual Acuity | 1 | 2017 | 64 | 0.610 |
Why?
|
Adult | 26 | 2022 | 8243 | 0.580 |
Why?
|
Acoustic Stimulation | 2 | 2015 | 57 | 0.570 |
Why?
|
Dental Health Services | 2 | 2012 | 8 | 0.530 |
Why?
|
Neural Pathways | 1 | 2015 | 56 | 0.530 |
Why?
|
Electric Stimulation | 1 | 2015 | 53 | 0.530 |
Why?
|
Emergency Service, Hospital | 4 | 2020 | 419 | 0.530 |
Why?
|
United States | 19 | 2023 | 3588 | 0.520 |
Why?
|
Health Services Accessibility | 4 | 2010 | 226 | 0.520 |
Why?
|
Hot Flashes | 1 | 2015 | 46 | 0.520 |
Why?
|
Models, Genetic | 3 | 2012 | 102 | 0.490 |
Why?
|
Glomerular Filtration Rate | 6 | 2021 | 307 | 0.470 |
Why?
|
Fluorides, Topical | 2 | 2010 | 4 | 0.460 |
Why?
|
Risk Factors | 18 | 2023 | 3520 | 0.460 |
Why?
|
Stomatognathic Diseases | 1 | 2012 | 5 | 0.450 |
Why?
|
Genes, MHC Class II | 1 | 2012 | 3 | 0.440 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 4 | 2020 | 27 | 0.440 |
Why?
|
Age Factors | 8 | 2019 | 1058 | 0.430 |
Why?
|
Uncertainty | 1 | 2012 | 11 | 0.430 |
Why?
|
Myocardial Contraction | 2 | 2009 | 57 | 0.430 |
Why?
|
Overweight | 4 | 2020 | 254 | 0.410 |
Why?
|
Cohort Studies | 9 | 2023 | 1673 | 0.410 |
Why?
|
HLA-DQ Antigens | 1 | 2011 | 9 | 0.400 |
Why?
|
HLA-DR Antigens | 1 | 2011 | 8 | 0.400 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 88 | 0.400 |
Why?
|
Child, Preschool | 13 | 2013 | 1126 | 0.390 |
Why?
|
Proxy | 1 | 2010 | 9 | 0.390 |
Why?
|
Bayes Theorem | 2 | 2011 | 59 | 0.380 |
Why?
|
Parents | 2 | 2010 | 115 | 0.370 |
Why?
|
Silene | 1 | 2009 | 1 | 0.370 |
Why?
|
Flowers | 1 | 2009 | 1 | 0.370 |
Why?
|
Selection, Genetic | 1 | 2009 | 12 | 0.370 |
Why?
|
Child | 16 | 2013 | 2151 | 0.370 |
Why?
|
Mental Health | 1 | 2010 | 93 | 0.360 |
Why?
|
Prevalence | 4 | 2022 | 881 | 0.340 |
Why?
|
Psychometrics | 1 | 2009 | 122 | 0.330 |
Why?
|
Adolescent | 18 | 2015 | 3184 | 0.330 |
Why?
|
Stroke | 2 | 2023 | 443 | 0.330 |
Why?
|
Residence Characteristics | 1 | 2010 | 166 | 0.330 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 379 | 0.330 |
Why?
|
Behavior Therapy | 2 | 2020 | 89 | 0.330 |
Why?
|
Cognition | 4 | 2023 | 512 | 0.330 |
Why?
|
Acute Coronary Syndrome | 2 | 2023 | 175 | 0.330 |
Why?
|
Ventricular Function, Left | 1 | 2009 | 201 | 0.320 |
Why?
|
Accidental Falls | 2 | 2019 | 77 | 0.320 |
Why?
|
Wisconsin | 7 | 2012 | 17 | 0.320 |
Why?
|
Follow-Up Studies | 10 | 2022 | 2027 | 0.300 |
Why?
|
Body Mass Index | 8 | 2016 | 890 | 0.290 |
Why?
|
African Americans | 8 | 2019 | 1513 | 0.290 |
Why?
|
Medicaid | 4 | 2011 | 82 | 0.290 |
Why?
|
Longitudinal Studies | 5 | 2021 | 694 | 0.290 |
Why?
|
Risk Assessment | 3 | 2020 | 1285 | 0.280 |
Why?
|
Creatinine | 3 | 2022 | 183 | 0.280 |
Why?
|
Haplotypes | 5 | 2015 | 255 | 0.280 |
Why?
|
Systole | 3 | 2020 | 90 | 0.280 |
Why?
|
Kidney Diseases | 2 | 2019 | 254 | 0.260 |
Why?
|
Cross-Sectional Studies | 7 | 2020 | 1345 | 0.260 |
Why?
|
Weight Loss | 4 | 2023 | 411 | 0.260 |
Why?
|
Brain | 4 | 2021 | 809 | 0.260 |
Why?
|
HIV-1 | 3 | 2015 | 39 | 0.250 |
Why?
|
HIV Infections | 3 | 2015 | 330 | 0.250 |
Why?
|
Alleles | 4 | 2015 | 273 | 0.250 |
Why?
|
Incidence | 4 | 2022 | 1087 | 0.250 |
Why?
|
Heart Failure | 2 | 2023 | 574 | 0.250 |
Why?
|
Treatment Outcome | 7 | 2023 | 2886 | 0.250 |
Why?
|
Hispanic Americans | 6 | 2013 | 935 | 0.240 |
Why?
|
Apolipoproteins | 2 | 2016 | 217 | 0.230 |
Why?
|
Lipoproteins, HDL | 2 | 2016 | 269 | 0.220 |
Why?
|
Cerebrovascular Circulation | 3 | 2022 | 90 | 0.220 |
Why?
|
Regression Analysis | 2 | 2016 | 266 | 0.220 |
Why?
|
Health Status Indicators | 2 | 2016 | 68 | 0.220 |
Why?
|
Retrospective Studies | 6 | 2017 | 2930 | 0.210 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2022 | 26 | 0.210 |
Why?
|
Homebound Persons | 1 | 2021 | 8 | 0.210 |
Why?
|
Dental Care | 3 | 2011 | 17 | 0.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 133 | 0.210 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2022 | 104 | 0.200 |
Why?
|
Survival Analysis | 2 | 2019 | 424 | 0.200 |
Why?
|
Immunoglobulin G | 2 | 2012 | 105 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2014 | 114 | 0.200 |
Why?
|
Health Surveys | 2 | 2019 | 189 | 0.200 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 706 | 0.200 |
Why?
|
Sample Size | 2 | 2012 | 37 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 6 | 2015 | 938 | 0.200 |
Why?
|
Diet Therapy | 1 | 2020 | 13 | 0.200 |
Why?
|
Body Height | 2 | 2011 | 31 | 0.200 |
Why?
|
Sex Factors | 3 | 2019 | 619 | 0.190 |
Why?
|
Bicarbonates | 1 | 2020 | 11 | 0.190 |
Why?
|
Cystatin C | 1 | 2020 | 29 | 0.190 |
Why?
|
Hospitalization | 2 | 2020 | 386 | 0.190 |
Why?
|
European Continental Ancestry Group | 7 | 2014 | 1203 | 0.190 |
Why?
|
Advance Care Planning | 1 | 2019 | 10 | 0.180 |
Why?
|
Documentation | 1 | 2019 | 32 | 0.180 |
Why?
|
Health Care Costs | 1 | 2020 | 106 | 0.180 |
Why?
|
Genetic Variation | 4 | 2019 | 278 | 0.180 |
Why?
|
Exercise Therapy | 1 | 2020 | 195 | 0.170 |
Why?
|
Activities of Daily Living | 1 | 2019 | 216 | 0.160 |
Why?
|
Infant | 6 | 2013 | 928 | 0.160 |
Why?
|
Data Collection | 1 | 2018 | 158 | 0.160 |
Why?
|
Dental Care for Children | 2 | 2009 | 4 | 0.160 |
Why?
|
Diet | 3 | 2020 | 346 | 0.160 |
Why?
|
Decision Making | 1 | 2019 | 154 | 0.160 |
Why?
|
Patient-Centered Care | 1 | 2018 | 67 | 0.160 |
Why?
|
Genotype | 4 | 2015 | 813 | 0.160 |
Why?
|
Retirement | 1 | 2017 | 10 | 0.160 |
Why?
|
Syncope | 1 | 2018 | 23 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 33 | 0.160 |
Why?
|
Mass Screening | 1 | 2019 | 218 | 0.160 |
Why?
|
Menopause | 2 | 2015 | 86 | 0.150 |
Why?
|
Vasodilation | 2 | 2016 | 92 | 0.150 |
Why?
|
Linkage Disequilibrium | 2 | 2015 | 222 | 0.150 |
Why?
|
Lipoproteins | 1 | 2017 | 82 | 0.150 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 1144 | 0.150 |
Why?
|
Postural Balance | 1 | 2017 | 109 | 0.140 |
Why?
|
Tilt-Table Test | 1 | 2015 | 13 | 0.140 |
Why?
|
Postural Orthostatic Tachycardia Syndrome | 1 | 2015 | 8 | 0.140 |
Why?
|
Allostasis | 1 | 2015 | 11 | 0.140 |
Why?
|
Healthcare Disparities | 2 | 2018 | 148 | 0.140 |
Why?
|
Vasoconstriction | 1 | 2016 | 42 | 0.140 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2015 | 3 | 0.140 |
Why?
|
Temporal Lobe | 1 | 2015 | 36 | 0.140 |
Why?
|
Frail Elderly | 1 | 2016 | 60 | 0.140 |
Why?
|
Genetics, Population | 2 | 2012 | 30 | 0.130 |
Why?
|
Gene Regulatory Networks | 2 | 2012 | 35 | 0.130 |
Why?
|
Claudins | 1 | 2015 | 9 | 0.130 |
Why?
|
Enhancer Elements, Genetic | 1 | 2015 | 17 | 0.130 |
Why?
|
Young Adult | 8 | 2015 | 2321 | 0.130 |
Why?
|
Interleukins | 1 | 2015 | 18 | 0.130 |
Why?
|
Disease Susceptibility | 1 | 2015 | 53 | 0.130 |
Why?
|
Anthrax | 2 | 2013 | 5 | 0.130 |
Why?
|
Oxygen | 1 | 2016 | 131 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 304 | 0.130 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2015 | 38 | 0.130 |
Why?
|
Prediabetic State | 1 | 2015 | 55 | 0.130 |
Why?
|
Radiosurgery | 1 | 2017 | 221 | 0.130 |
Why?
|
DNA Copy Number Variations | 2 | 2011 | 13 | 0.130 |
Why?
|
Mitochondrial Proteins | 1 | 2015 | 68 | 0.130 |
Why?
|
Body Weight | 2 | 2020 | 289 | 0.130 |
Why?
|
Major Histocompatibility Complex | 1 | 2014 | 15 | 0.130 |
Why?
|
Social Class | 3 | 2009 | 71 | 0.120 |
Why?
|
Adiponectin | 1 | 2015 | 117 | 0.120 |
Why?
|
Information Storage and Retrieval | 1 | 2014 | 22 | 0.120 |
Why?
|
Physical Fitness | 1 | 2015 | 114 | 0.120 |
Why?
|
Vitamin D | 1 | 2015 | 174 | 0.120 |
Why?
|
Physicians' Offices | 2 | 2011 | 9 | 0.120 |
Why?
|
Neoplasms | 1 | 2020 | 596 | 0.120 |
Why?
|
Models, Statistical | 2 | 2012 | 157 | 0.120 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2014 | 9 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2015 | 700 | 0.120 |
Why?
|
Phenotype | 3 | 2011 | 653 | 0.120 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2014 | 29 | 0.120 |
Why?
|
Diabetic Retinopathy | 1 | 2014 | 69 | 0.120 |
Why?
|
Indoles | 1 | 2014 | 51 | 0.120 |
Why?
|
Dentists | 2 | 2011 | 2 | 0.120 |
Why?
|
Promoter Regions, Genetic | 2 | 2012 | 218 | 0.120 |
Why?
|
Geriatric Assessment | 1 | 2016 | 328 | 0.120 |
Why?
|
Appendectomy | 1 | 2013 | 15 | 0.120 |
Why?
|
Heart Rate | 1 | 2015 | 325 | 0.120 |
Why?
|
Appendicitis | 1 | 2013 | 13 | 0.120 |
Why?
|
Bacillus anthracis | 1 | 2013 | 9 | 0.120 |
Why?
|
Medically Underserved Area | 2 | 2011 | 22 | 0.120 |
Why?
|
Diabetic Angiopathies | 1 | 2014 | 150 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2013 | 20 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 44 | 0.120 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2014 | 125 | 0.110 |
Why?
|
Animals | 7 | 2015 | 6402 | 0.110 |
Why?
|
Pregnancy | 1 | 2015 | 799 | 0.110 |
Why?
|
Depression | 1 | 2015 | 361 | 0.110 |
Why?
|
Calcifediol | 1 | 2012 | 7 | 0.110 |
Why?
|
Bipolar Disorder | 1 | 2012 | 15 | 0.110 |
Why?
|
Estrogens | 1 | 2014 | 170 | 0.110 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2012 | 32 | 0.110 |
Why?
|
Cadherins | 1 | 2012 | 24 | 0.110 |
Why?
|
Health Policy | 2 | 2010 | 73 | 0.110 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 4 | 0.110 |
Why?
|
Risk | 3 | 2020 | 290 | 0.110 |
Why?
|
Students, Medical | 1 | 2014 | 115 | 0.110 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 521 | 0.110 |
Why?
|
Epistasis, Genetic | 1 | 2012 | 50 | 0.110 |
Why?
|
Antibodies, Bacterial | 1 | 2012 | 31 | 0.110 |
Why?
|
Curriculum | 1 | 2014 | 189 | 0.110 |
Why?
|
Brain Neoplasms | 1 | 2017 | 471 | 0.110 |
Why?
|
Diabetic Nephropathies | 1 | 2014 | 246 | 0.110 |
Why?
|
Receptors, Interleukin | 1 | 2011 | 12 | 0.110 |
Why?
|
Cholesterol, HDL | 1 | 2012 | 170 | 0.110 |
Why?
|
RNA-Binding Proteins | 1 | 2012 | 69 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2011 | 51 | 0.100 |
Why?
|
Quantitative Trait, Heritable | 1 | 2011 | 51 | 0.100 |
Why?
|
Atherosclerosis | 1 | 2017 | 725 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2011 | 58 | 0.100 |
Why?
|
Longevity | 1 | 2010 | 20 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2011 | 144 | 0.100 |
Why?
|
Smallpox Vaccine | 1 | 2010 | 2 | 0.100 |
Why?
|
Prospective Studies | 5 | 2016 | 1932 | 0.100 |
Why?
|
Gene Frequency | 1 | 2011 | 272 | 0.100 |
Why?
|
Genome, Human | 1 | 2011 | 148 | 0.100 |
Why?
|
Counseling | 2 | 2020 | 84 | 0.090 |
Why?
|
Ryanodine Receptor Calcium Release Channel | 1 | 2010 | 18 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2011 | 187 | 0.090 |
Why?
|
Research Design | 1 | 2012 | 271 | 0.090 |
Why?
|
Calcium | 1 | 2012 | 276 | 0.090 |
Why?
|
Fee-for-Service Plans | 1 | 2010 | 10 | 0.090 |
Why?
|
Birds | 1 | 2009 | 4 | 0.090 |
Why?
|
Ultrasonography | 2 | 2009 | 347 | 0.090 |
Why?
|
Female Athlete Triad Syndrome | 1 | 2009 | 2 | 0.090 |
Why?
|
Managed Care Programs | 1 | 2010 | 40 | 0.090 |
Why?
|
Cause of Death | 3 | 2016 | 219 | 0.090 |
Why?
|
Indians, North American | 1 | 2010 | 111 | 0.090 |
Why?
|
Cariostatic Agents | 1 | 2009 | 3 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2010 | 60 | 0.090 |
Why?
|
Urban Population | 1 | 2010 | 80 | 0.090 |
Why?
|
Biomedical Research | 1 | 2010 | 144 | 0.090 |
Why?
|
Athletes | 1 | 2009 | 62 | 0.090 |
Why?
|
Language | 1 | 2009 | 43 | 0.090 |
Why?
|
Hypopharynx | 1 | 2008 | 2 | 0.090 |
Why?
|
Mucins | 1 | 2008 | 18 | 0.080 |
Why?
|
Computer Simulation | 1 | 2009 | 187 | 0.080 |
Why?
|
Larynx | 1 | 2008 | 19 | 0.080 |
Why?
|
Gastroesophageal Reflux | 1 | 2008 | 23 | 0.080 |
Why?
|
Orthodontics, Corrective | 1 | 2008 | 1 | 0.080 |
Why?
|
Office Visits | 1 | 2008 | 71 | 0.080 |
Why?
|
Case-Control Studies | 4 | 2012 | 886 | 0.080 |
Why?
|
Rural Population | 1 | 2010 | 244 | 0.080 |
Why?
|
Health Personnel | 1 | 2009 | 103 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2011 | 494 | 0.080 |
Why?
|
Bone Density | 1 | 2009 | 192 | 0.080 |
Why?
|
Amenorrhea | 1 | 2007 | 3 | 0.080 |
Why?
|
Running | 1 | 2007 | 16 | 0.080 |
Why?
|
Pain | 1 | 2010 | 247 | 0.080 |
Why?
|
Tissue Survival | 1 | 2007 | 12 | 0.080 |
Why?
|
Organ Size | 2 | 2019 | 204 | 0.080 |
Why?
|
Brachial Artery | 1 | 2007 | 65 | 0.080 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 774 | 0.080 |
Why?
|
Orthodontics | 1 | 2007 | 1 | 0.080 |
Why?
|
Malocclusion | 1 | 2007 | 5 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 858 | 0.070 |
Why?
|
Oxygenases | 1 | 2006 | 3 | 0.070 |
Why?
|
Age Distribution | 3 | 2016 | 197 | 0.070 |
Why?
|
Echocardiography | 1 | 2007 | 142 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 149 | 0.070 |
Why?
|
Kidney Function Tests | 2 | 2016 | 108 | 0.070 |
Why?
|
Thrombospondin 1 | 1 | 2005 | 6 | 0.070 |
Why?
|
Myocardium | 1 | 2007 | 197 | 0.070 |
Why?
|
Erythrocytes | 1 | 2005 | 42 | 0.070 |
Why?
|
Health Expenditures | 2 | 2020 | 60 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2015 | 171 | 0.070 |
Why?
|
Exercise | 2 | 2020 | 567 | 0.060 |
Why?
|
Internationality | 1 | 2023 | 19 | 0.060 |
Why?
|
Genetic Loci | 2 | 2015 | 162 | 0.060 |
Why?
|
Diffusion Tensor Imaging | 1 | 2023 | 26 | 0.060 |
Why?
|
Motor Activity | 2 | 2015 | 251 | 0.050 |
Why?
|
Waist Circumference | 2 | 2012 | 90 | 0.050 |
Why?
|
Kidney Tubules | 1 | 2021 | 28 | 0.050 |
Why?
|
Adiposity | 2 | 2015 | 208 | 0.050 |
Why?
|
Lipids | 1 | 2023 | 215 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 156 | 0.050 |
Why?
|
Independent Living | 1 | 2021 | 62 | 0.050 |
Why?
|
Program Evaluation | 2 | 2014 | 166 | 0.050 |
Why?
|
Medicare Part A | 1 | 2020 | 5 | 0.050 |
Why?
|
Medicare Part B | 1 | 2020 | 5 | 0.050 |
Why?
|
Medicare Part D | 1 | 2020 | 8 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2020 | 14 | 0.050 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 49 | 0.050 |
Why?
|
Health Services | 1 | 2020 | 35 | 0.050 |
Why?
|
Nutrition Surveys | 2 | 2011 | 135 | 0.050 |
Why?
|
Time Factors | 2 | 2016 | 1874 | 0.050 |
Why?
|
Terminal Care | 1 | 2019 | 17 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 89 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2020 | 202 | 0.040 |
Why?
|
Patient Participation | 1 | 2019 | 60 | 0.040 |
Why?
|
Albuminuria | 1 | 2020 | 207 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 381 | 0.040 |
Why?
|
Sex Distribution | 2 | 2010 | 187 | 0.040 |
Why?
|
Gender Identity | 1 | 2018 | 18 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2019 | 52 | 0.040 |
Why?
|
Chronic Disease | 1 | 2019 | 359 | 0.040 |
Why?
|
Medical Oncology | 1 | 2018 | 70 | 0.040 |
Why?
|
Algorithms | 2 | 2012 | 456 | 0.040 |
Why?
|
Survival Rate | 1 | 2020 | 775 | 0.040 |
Why?
|
Sexual Behavior | 1 | 2018 | 99 | 0.040 |
Why?
|
Nomograms | 1 | 2017 | 23 | 0.040 |
Why?
|
Death | 1 | 2017 | 40 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 152 | 0.040 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 87 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 23 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 279 | 0.040 |
Why?
|
Exercise Test | 1 | 2017 | 192 | 0.040 |
Why?
|
Logistic Models | 2 | 2009 | 727 | 0.040 |
Why?
|
Animal Feed | 1 | 2015 | 14 | 0.040 |
Why?
|
Potassium Channels, Voltage-Gated | 1 | 2015 | 13 | 0.030 |
Why?
|
Rest | 1 | 2016 | 47 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 369 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2017 | 216 | 0.030 |
Why?
|
Posture | 1 | 2015 | 48 | 0.030 |
Why?
|
Models, Neurological | 1 | 2016 | 63 | 0.030 |
Why?
|
Medication Adherence | 1 | 2017 | 146 | 0.030 |
Why?
|
Rats | 2 | 2010 | 1425 | 0.030 |
Why?
|
Baroreflex | 1 | 2015 | 90 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2015 | 90 | 0.030 |
Why?
|
Recurrence | 1 | 2015 | 210 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2017 | 235 | 0.030 |
Why?
|
Weight Gain | 1 | 2015 | 101 | 0.030 |
Why?
|
Computational Biology | 1 | 2015 | 87 | 0.030 |
Why?
|
Librarians | 1 | 2014 | 1 | 0.030 |
Why?
|
Africa | 1 | 2014 | 24 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2015 | 171 | 0.030 |
Why?
|
Models, Biological | 1 | 2016 | 356 | 0.030 |
Why?
|
Pilot Projects | 1 | 2015 | 437 | 0.030 |
Why?
|
Basilar Artery | 1 | 2014 | 7 | 0.030 |
Why?
|
Problem-Based Learning | 1 | 2014 | 25 | 0.030 |
Why?
|
Viral Load | 1 | 2014 | 63 | 0.030 |
Why?
|
Carotid Artery, Internal | 1 | 2014 | 20 | 0.030 |
Why?
|
Haplorhini | 1 | 2014 | 48 | 0.030 |
Why?
|
Diet, Atherogenic | 1 | 2014 | 61 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 498 | 0.030 |
Why?
|
Drug Combinations | 1 | 2014 | 83 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 2 | 0.030 |
Why?
|
Random Allocation | 1 | 2014 | 186 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2013 | 15 | 0.030 |
Why?
|
African Continental Ancestry Group | 1 | 2015 | 376 | 0.030 |
Why?
|
Homozygote | 1 | 2013 | 61 | 0.030 |
Why?
|
Heterozygote | 1 | 2013 | 54 | 0.030 |
Why?
|
Lymphocytes | 1 | 2013 | 52 | 0.030 |
Why?
|
Databases, Factual | 1 | 2014 | 320 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2013 | 80 | 0.030 |
Why?
|
Acute Disease | 1 | 2013 | 234 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2012 | 24 | 0.030 |
Why?
|
Artificial Intelligence | 1 | 2012 | 45 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 436 | 0.030 |
Why?
|
OX40 Ligand | 1 | 2011 | 6 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 7 | 0.030 |
Why?
|
Vitamins | 1 | 2012 | 56 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 211 | 0.030 |
Why?
|
Vaccination | 1 | 2013 | 118 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2013 | 480 | 0.030 |
Why?
|
Models, Animal | 1 | 2012 | 148 | 0.030 |
Why?
|
Crohn Disease | 1 | 2011 | 25 | 0.030 |
Why?
|
Alberta | 1 | 2011 | 1 | 0.030 |
Why?
|
Colitis, Ulcerative | 1 | 2011 | 20 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 31 | 0.030 |
Why?
|
Tooth Diseases | 1 | 2011 | 5 | 0.030 |
Why?
|
Periodontal Diseases | 1 | 2011 | 13 | 0.030 |
Why?
|
Self Concept | 1 | 2011 | 40 | 0.030 |
Why?
|
Urban Health | 1 | 2011 | 13 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 587 | 0.030 |
Why?
|
Linear Models | 1 | 2012 | 421 | 0.030 |
Why?
|
Rural Health | 1 | 2011 | 43 | 0.030 |
Why?
|
Mouth Diseases | 1 | 2011 | 21 | 0.030 |
Why?
|
Fasting | 1 | 2011 | 98 | 0.020 |
Why?
|
Retinoid X Receptor alpha | 1 | 2010 | 1 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 567 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2010 | 8 | 0.020 |
Why?
|
Triglycerides | 1 | 2011 | 220 | 0.020 |
Why?
|
Genes | 1 | 2010 | 15 | 0.020 |
Why?
|
Poverty | 1 | 2011 | 98 | 0.020 |
Why?
|
Markov Chains | 1 | 2010 | 26 | 0.020 |
Why?
|
Prognosis | 1 | 2014 | 1342 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2010 | 28 | 0.020 |
Why?
|
Midwestern United States | 1 | 2009 | 9 | 0.020 |
Why?
|
Comorbidity | 1 | 2011 | 531 | 0.020 |
Why?
|
Communication Barriers | 1 | 2009 | 20 | 0.020 |
Why?
|
Energy Intake | 1 | 2009 | 122 | 0.020 |
Why?
|
Pepsin A | 1 | 2008 | 8 | 0.020 |
Why?
|
Epithelium | 1 | 2008 | 21 | 0.020 |
Why?
|
Income | 1 | 2009 | 50 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2008 | 65 | 0.020 |
Why?
|
Minority Groups | 1 | 2009 | 69 | 0.020 |
Why?
|
Pain Measurement | 1 | 2010 | 328 | 0.020 |
Why?
|
Marital Status | 1 | 2008 | 21 | 0.020 |
Why?
|
Educational Status | 1 | 2009 | 162 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 317 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 236 | 0.020 |
Why?
|
Down-Regulation | 1 | 2008 | 138 | 0.020 |
Why?
|
Dilatation, Pathologic | 1 | 2007 | 19 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2007 | 80 | 0.020 |
Why?
|
Dental Health Surveys | 1 | 2007 | 1 | 0.020 |
Why?
|
Insurance, Dental | 1 | 2007 | 1 | 0.020 |
Why?
|
Gene Expression | 1 | 2008 | 324 | 0.020 |
Why?
|
Continental Population Groups | 1 | 2008 | 229 | 0.020 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2007 | 19 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2007 | 88 | 0.020 |
Why?
|
Oral Health | 1 | 2007 | 29 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2008 | 498 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2007 | 240 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2007 | 135 | 0.020 |
Why?
|
Kinetics | 1 | 2006 | 185 | 0.020 |
Why?
|
Erythrocyte Membrane | 1 | 2005 | 1 | 0.020 |
Why?
|
Nystatin | 1 | 2005 | 2 | 0.020 |
Why?
|
Osmosis | 1 | 2005 | 3 | 0.020 |
Why?
|
Erythrocytes, Abnormal | 1 | 2005 | 2 | 0.020 |
Why?
|
Sucrose | 1 | 2005 | 7 | 0.020 |
Why?
|
Dehydration | 1 | 2005 | 7 | 0.020 |
Why?
|
Capillaries | 1 | 2005 | 23 | 0.020 |
Why?
|
Phosphatidylserines | 1 | 2005 | 8 | 0.020 |
Why?
|
Women's Health | 1 | 2007 | 226 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2005 | 104 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 624 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2005 | 169 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2005 | 779 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2007 | 915 | 0.010 |
Why?
|
Kidney | 1 | 2005 | 495 | 0.010 |
Why?
|
Mice | 1 | 2005 | 2181 | 0.010 |
Why?
|